Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Germany to pump €1bn into breakthrough innovation

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be...

ReViral raises US$55m

ReViral focusses on infections caused by the Respiratory Syncytial Virus (RSV). It is the most important respiratory pathogen, with 30 million...

Matrikines give hint to new asthma meds

The results http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aaq0693 of a British-Spanish-Polish research team headed by Dhiren...

IMI to spur on antibiotics research amidst big pharma pullback

The new IMI AMR Accelerator aims to progress the development of new treatments and vaccines for resistant bacterial infections. It “represents a...

Urovant Sciences licenses OAB gene therapy

hMaxi-K adds to the public Swiss company’s lead product candidate in OAB, vibegron, an oral, once-daily, small molecule beta-3 agonist,...

Genkyotex cashes in €7.5m

The company secured the proceeds through the issuance of convertible notes with share subscription warrants attached to YA II PN, LTD, an investment...

CRISPR-gene drive safely kills mosquitos

Gene drives are built to spread specific genes throughout a population within a few generations by biasing inheritance of the genes in offspring. In...